Posts Tagged ‘Lilly’

Tirzepatide: Two for One Efficacy? Diabetes + Obesity?

December 10, 2020 — News from Eli Lilly and Company suggests that we may soon see a new drug that offers two-for-one efficacy – a clinical benefit in both obesity and diabetes. The company announced yesterday that tirzepatide produced good results against endpoints for both diseases in a phase 3 RCT. In this study, called SURPASS-1, researchers tested three […]

Lilly Decides to Advance Tirzepatide for Obesity

June 14, 2019 — It was odd. Lilly had a promising new drug for diabetes that delivered unusually good weight outcomes. But they weren’t sure about developing it for obesity. That was last October. Now, though, they seem to have decided to move ahead with their dual GIP/GLP-1 agonist, tirzepatide, for obesity. Pivotal phase 3 trials will begin this […]